Semaphorins as Potential Immune Therapeutic Targets for Cancer. 2022

Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
Department of Health Service, Fourth Military Medical University, Xi'an, China.

Semaphorins are a large class of secreted or membrane-bound molecules. It has been reported that semaphorins play important roles in regulating several hallmarks of cancer, including angiogenesis, metastasis, and immune evasion. Semaphorins and their receptors are widely expressed on tumor cells and immune cells. However, the biological role of semaphorins in tumor immune microenvironment is intricate. The dysregulation of semaphorins influences the recruitment and infiltration of immune cells, leading to abnormal anti-tumor effect. Although the underlying mechanisms of semaphorins on regulating tumor-infiltrating immune cell activation and functions are not fully understood, semaphorins can notably be promising immunotherapy targets for cancer.

UI MeSH Term Description Entries

Related Publications

Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
August 2014, Nature reviews. Drug discovery,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
August 2012, Cancer cell,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
January 2018, American journal of respiratory cell and molecular biology,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
January 2021, Theranostics,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
June 2021, International immunopharmacology,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
April 2020, BMC medical genomics,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
January 2022, Chinese medical journal,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
December 2023, Pharmacological research,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
January 2018, ImmunoTargets and therapy,
Jun Jiang, and Fang Zhang, and Yi Wan, and Ke Fang, and Ze-Dong Yan, and Xin-Ling Ren, and Rui Zhang
March 2015, Expert opinion on therapeutic targets,
Copied contents to your clipboard!